About CASTLEVAX INC
CastleVax is a clinical-stage biotechnology company developing mucosal vaccines using a novel platform based on Newcastle Disease Virus (NDV). The company is focused on creating safe, effective, and rapidly deployable vaccines for a range of infectious diseases.
Development of mucosal vaccines using a Newcastle Disease Virus (NDV) platformRapid vaccine development for respiratory and other infectious diseasesPhase 2 clinical trials for next-generation COVID-19 vaccinesPipeline of vaccine candidates including RSV+ HMPV and Norovirus vaccines
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| DEVELOP A NEXT-GENERATION, MUCOSALLY DELIVERED, COVID-19 BOOSTER VACCINE CAPABLE OF ELICITING MUCOSAL IMMUNITY | Department of Health and Human Services | $8.3M |
Is this your company?
Claim CASTLEVAX INC to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.
Claim CASTLEVAX INC & see your matchesFree to claim. Takes about a minute.
Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.